ID
42247
Beskrivning
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS. https://clinicaltrials.gov/ct2/show/NCT00391872
Länk
https://clinicaltrials.gov/ct2/show/NCT00391872
Nyckelord
Versioner (3)
- 2015-11-28 2015-11-28 -
- 2021-04-14 2021-04-14 - Ahmed Rafee, MD
- 2021-04-15 2021-04-15 - Ahmed Rafee, MD
Rättsinnehavare
AstraZeneca
Uppladdad den
15 april 2021
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Inga kommentarer